Mance E. Buttram Source Confirmed

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI

Associate Professor

University of Arkansas at Fayetteville

faculty

19 h-index 128 pubs 1,205 cited

Research Areas

Opioid Use Disorder Treatment Substance Abuse Treatment and Outcomes Pharmacological Effects and Toxicity Studies Health disparities and outcomes Behavioral Health and Interventions Mental Health Research Topics Healthcare Policy and Management Health and Medical Research Impacts

Links

ORCID Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Mance E. Buttram's research focuses on understanding and addressing substance use disorders, particularly opioid use disorder (OUD), and related health outcomes. He has investigated the nonmedical use of medications, such as gabapentin, in conjunction with opioid agonist treatments like buprenorphine. His work also examines the prevalence and motivations behind the use of substances like kratom and the diversion of buprenorphine within the United States.

Buttram's research extends to public health issues associated with substance use, including the association between transactional sex and sexually transmitted infections among individuals seeking treatment for OUD. He also studies geographic and racial/ethnic disparities in access to essential healthcare services, such as methamphetamine detoxification. His scholarship is supported by federal grants, including funding from the NIH/National Institute on Drug Abuse for a project examining the concomitant non-medical use of gabapentin and opioids. Buttram has published extensively, with a h-index of 19 and over 1,200 citations across 128 publications. He leads a research group at the University of Arkansas at Fayetteville and collaborates with colleagues within the institution.

Metrics

h-index: 19
Publications: 128
Citations: 1,205

Selected Publications

Gabapentin-Related State Policies and Associations with Gabapentin Non-Medical Use Among a Nationally Representative Population in the United States (2025) DOI
Pharmaceutical stimulant diversion, 2002–2022: data from a national sample of law enforcement and regulatory agencies in the US (2025) DOI
It’s Like Disney … You Have to Find Them a Fantasy: Latino Sexual Minority Men at the Intersection of Tourism, Sex, Drug Use, and HIV in Miami-South Beach (2025) DOI
Recreational Ketamine Use among Individuals with Opioid Use Disorder: Demographics, Motivations, and Polysubstance Use (2025) DOI
Pharmaceutical Stimulant Diversion, 2002-2022: Data from a National Sample of Law Enforcement and Regulatory Agencies (2025) DOI
The Informal, Non-Prescribed Use of Antiretroviral Medications for PrEP Among a National US-Based Sample of Gay, Bisexual, and Other Men Who Have Sex with Men: A Cross-Sectional Study (2024) DOI
Understanding Ketamine Use in Treatment-Seeking Persons With Opioid Use Disorder (2024) DOI
GABAPENTIN UTILIZATION AMONG BUPRENORPHINE-PRESCRIBED INDIVIDUALS WITH OPIOID USE DISORDER AND ASSOCIATED RISK OF OVERDOSE (2024) DOI
Associations Between Kratom-Related State Policy Environments and Kratom Use in a Nationally Representative Population in the United States (2024) DOI
Geographic and Racial/Ethnic Differences in Access to Methamphetamine Detoxification Services, United States, 2021 (2024) DOI
Stigma Related to the Non-Medical Use and Diversion of Prescription Stimulant Drugs: Should We Care (2024) DOI
Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder (2023) DOI
Law enforcement experiences with gabapentin: non-medical use, diversion, and state controlled substances laws (2023) DOI
Associations Between Kratom-Related State Policy Environments and Kratom Use in a Nationally Representative Population in the United States (2023) DOI
Sexual HIV transmission risk behaviors associated with stimulant drug injection among people who non-medically use gabapentin and opioids (2022) DOI